Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lev and Plasma Centers of America sign supply agreement
The terms of this agreement are subject to certain provisions and performance targets as outlined in Lev’s filing on Form 8-K with the Securities and Exchange Commission. Judson
The terms of this agreement are subject to certain provisions and performance targets as outlined in Lev’s filing on Form 8-K with the Securities and Exchange Commission. Judson
This patent is the first granted to Advanced Viral Research (ADVR) in Europe. ADVR has an extensive portfolio of the US and foreign patents including 22 issued in
This drug candidate is the ocular formulation of sonepcizumab, a humanized monoclonal antibody against sphingosine-1-phosphate. The company expects to begin Phase I clinical trials of iSONEP as a
The data were generated from three blinded studies of preclinical models of colon carcinoma randomized into three experimental groups. The models were treated with suboptimal doses of motesanib
Dr Mueller will be actively involved in the development of strategic alliances and business opportunities with other companies and organizations. Most recently, he has headed Epicenter Consulting, a
The system will be used for the treatment of immune-mediated diseases such as acute or chronic graft-versus-host disease and cutaneous T-cell lymphoma. Therakos Cellex photopheresis system is the
Antisoma will make an immediate upfront payment and fund certain research at Betagenon. Further payments will be made on achievement of development and regulatory milestones, and royalties will
In a novel mouse model of medulloblastoma, once-daily dose administration of IPI-926 resulted in 100% survival while on treatment and median overall survival of 48 days, a four-fold
PDI currently intends to deploy approximately 100 full-time equivalent sales representatives who will call upon physicians nationwide. Novartis will continue to be responsible for manufacturing, regulatory, medical, clinical
Ms Sainz succeeds Gary Curtis, who served as the CEO of the company since July 2002 and who recently decided to step down. Most recently Ms Sainz was